That Little Pink Pill


Take note consumers, big pharma wants you to buy its newest creation, a pill they’ve named the “little pink pill.” The “little pink pill” is being touted as the female version of that “little blue pill,” Viagra. Nothing could be further from the truth.

My readers know me as someone who loves to reduce the fraction when it comes to getting to the bottom of something. And to get to the bottom of the latest marketing fraud you have to come to grips with a widespread fallacy: Men and Women are two sides of the same coin. Sorry, simply not scientifically valid. Only in the minds of social engineers are the genders two sides of the same coin.

Viagra works peripherally. Without getting into the weeds on Viagra’s mechanism of action, the drug dilates blood vessels without affecting the patient’s neurochemistry. The little pink pill, on the other hand, changes brain chemistry in dramatic ways. Pinky increases two neurotransmitters and reduces the presence of a third. Dopamine and Noradrenaline are increased, while Serotonin is decreased. And why are we changing brain chemistry as though it is a benign as changing one’s socks? Supposedly, it is to increase a woman’s libido. Perhaps it will help you to learn a little bit about the origins of big pharma’s latest creation.

Flibansterin (Fly•Ban•Stair•N) (FLY) was originally designed by a German pharmaceutical manufacturer by the name of Boehringer Ingelheim. And what do you think the drug was originally designed to treat? If you answered depression you ‘d be correct. Problem was, the drug didn’t work. In 2010 Boehringer Ingelheim applied to the FDA for approval for their failed depression drug to treat female hypoactive sexual disorder. The clinical trials showed that the women who took FLY had 2.5 sexually satisfying events over a one-month period. Sounds OK, right? Well, the women in the study who took a placebo (sugar pill) had 1.5 sexually satisfying events over a one-month period. It wasn’t just FLY’S failure to make a dramatic difference that motivated the FDA to turn down Boehringer Ingelheim’s petition to approve the drug. The FDA expressed concerns about the long-term safety of FLY. After all, FLY does alter brain chemistry in some pretty profound ways.

In 2013 FLY was purchased by Sprout. Sprout is a pharmaceutical manufacturer that has, to my knowledge, only one drug it wants to sell to the public, and that’s FLY. The FDA turned down Sprout’s petition to them in 2013-14, just like it had turned down Boehringer Ingelheim’s petition to them. However, as if to prove the value of never giving up, the FDA may have given the green light to Sprout to market this drug.

The media’s slobbering idiocy when it comes to filling air time with any story that has sex in it along with their desire to help the American female public consider adding one more pill to their already full pill case, is enough to make me want to add a new diagnostic category to the DSM 5. ENOUGHPILLSALREADY Syndrome.

May I ask this simple question? Whatever happened to a glass of Chardonnay in front of a fireplace, maybe mixed in with a little romantic music? I don’t think a sugar pill can compete with that combination and I do not have any long-term safety concerns as long as you keep an eye on the fire. Now I’m not recommending it, but low dose Marijuana has been used for thousands of years to increase a woman’s libido without any of the long-term problems associated with FLY.

If women aren’t feeling sexual, far be it from me to suggest that perhaps there are more psychological and cultural reasons why that may be true. Here is one you may not have considered, perhaps you just don’t want to have sex with the men in your life. Maybe it is because men and women compete with one another. Maybe it is because women are too masculine and men are too feminine. And don’t get me started, maybe it is because couples these days are too busy spending money they don’t have to impress people they don’t like. You think?


Featured Posts
Recent Posts
Archive
Search By Tags
No tags yet.

© 2016 NAPOLEON LEGAL CONSULTING, INC. All rights reserved.